BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N, Hirano K, Toda N, Tada M, Omata M, Koike K. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013; 19(1): 72-77 [PMID: 23326165 DOI: 10.3748/wjg.v19.i1.72] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Sakai Y, Sugiyama H, Kawaguchi Y, Kawashima Y, Hirata N, Nakaji S, Natsui M, Shioji K, Nakahara K, Tsuyuguchi T, Kato N. Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial. Scand J Gastroenterol 2021;:1-7. [PMID: 34375164 DOI: 10.1080/00365521.2021.1938207] [Reference Citation Analysis]
2 Zheng T, Jin J, Zhou L, Zhang Y. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. Oncol Res Treat 2020;43:460-9. [PMID: 32629449 DOI: 10.1159/000507093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Sakai Y, Iwai T, Shimura K, Gon K, Koizumi K, Ijima M, Chiba K, Nakatani S, Sugiyama H, Tsuyuguchi T, Kamisawa T, Maetani I, Kida M. Safety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients. World J Gastroenterol 2018; 24(1): 69-75 [PMID: 29358883 DOI: 10.3748/wjg.v24.i1.69] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Chang J, Jang J, Lee KB, Kang MJ, Jung W, Shin YC, Kim S. Improvement of clinical outcomes in the patients with gallbladder cancer: lessons from periodic comparison in a tertiary referral center: Clinical Outcome of Gallbladder Cancer. J Hepatobiliary Pancreat Sci 2016;23:234-41. [DOI: 10.1002/jhbp.330] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Onesti CE, Romiti A, Roberto M, Falcone R, Marchetti P. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Rev Anticancer Ther 2015;15:1183-98. [PMID: 26325474 DOI: 10.1586/14737140.2015.1081816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y, Maetani I, Koike K. Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer. World J Gastroenterol 2014; 20(48): 18452-18457 [PMID: 25561816 DOI: 10.3748/wjg.v20.i48.18452] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Bae BC, Yang SG, Jeong S, Lee DH, Na K, Kim JM, Costamagna G, Kozarek RA, Isayama H, Deviere J, Seo DW, Nageshwar Reddy D. Polymeric photosensitizer-embedded self-expanding metal stent for repeatable endoscopic photodynamic therapy of cholangiocarcinoma. Biomaterials. 2014;35:8487-8495. [PMID: 25043500 DOI: 10.1016/j.biomaterials.2014.07.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
8 Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25:2328-2338. [PMID: 24769639 DOI: 10.1093/annonc/mdu162] [Cited by in Crossref: 155] [Cited by in F6Publishing: 232] [Article Influence: 19.4] [Reference Citation Analysis]
9 Sasaki T, Isayama H, Nakai Y, Koike K. Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med. 2013;28:515-524. [PMID: 24009445 DOI: 10.3904/kjim.2013.28.5.515] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]